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Bile acids play an important role in post-prandial glucose metabolism by stimulating release of glucagon-like
peptide-1 (GLP-1) via the G-protein-coupled receptor TGR5, which is expressed in intestinal L cells. Thus, bile acid
sequestrants are expected to stimulate secretion of endogenous GLP-1 through TGR5. We investigated incretin and
insulin secretion after a meal with and without ursodeoxycholic acid (UDCA), a widely used therapeutic agent in
liver diseases, in 7 non-diabetic Japanese subjects. We found that UDCA intake resulted in higher GLP-1 secretion
(area under the curve [AUC] of 0–60 min after meal without UDCA, 450 ± 162 mmol·min/l; with UDCA, 649 ±
232 mmol·min/l, P = 0.046) and lower blood glucose (AUC of 0–60 min without UDCA, 7191 ± 250 mg·min/dl; with
UDCA, 6716 ± 189 mg·min/dl, P = 0.001) , although we did not find statistically significant insulin increase by UDCA
intake (AUC of 0–60 min without UDCA, 1551 ± 418 μU·min/ml; with UDCA, 1941 ± 246 μU·min/ml, P = 0.065).
These results suggest that UDCA increases bile-induced GLP-1 secretion. Ours is the first report showing increased
GLP-1 secretion and decreased blood glucose in response to UDCA.
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Glucagon-like peptide-1 (GLP-1) is major incretins
released from gut endocrine cells in response to nutrient
ingestion. Notably, GLP-1 not only stimulates insulin
biosynthesis and secretion and promotes beta cell prolif-
eration, but also inhibits glucose production and gluca-
gon secretion by the liver, and reduces appetite and food
intake (Nauck et al. 1989; Kreymann et al. 1987; Trumper
et al. 2001; Xu et al. 2006; Prigeon et al. 2003; Flint et al.
1998; Gutzwiller et al. 1999). For these reasons, drugs
that increase GLP-1 activity have become attractive
therapeutic options for patients with type 2 diabetes
(Campbell and Miller 2009). GLP-1 receptor agonists
(incretin or GLP-1 mimetics) and dipeptidyl peptidase-4
(DPP-4) inhibitors (CD26 antigen inhibitors) are the
currently available incretin-based therapies proven to be
safe and effective in the management of type 2 diabetes
(Amori et al. 2007). However, they do not increase secre-
tion of endogenous GLP-1, and therapies that directly* Correspondence: t-horiuchi@toshima-hp.jp
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are expected to be effective.
Bile acids, the principal constituents of bile, along with
cholesterol, phospholipids, and bilirubin, have been
shown to stimulate GLP-1 secretion. GLP-1 levels were
found to increase in the portal effluent, following the lu-
minal perfusion of bile into perfused rat colon prepara-
tions (Plaisancie et al. 1995). Furthermore, bile acid
sequestrants have been found to increase plasma GLP-1
levels in human and rodents (Chen et al. 2010; Shang
et al. 2010; Garg et al. 2011; Suzuki et al. 2007). In
addition, high concentrations of bile acids in direct
contact with L-cell-rich regions of the intestine may
contribute to the rapid remission of type 2 diabetes after
gastric bypass surgery (Nakatani et al. 2009; Patti et al.
2009). Recently, a bile acid-sensitive G-protein-coupled
receptor (GPCR), TGR5, was described (Maruyama et al.
2002), whose activation results in enhanced GLP-1
secretion (Katsuma et al. 2005; Thomas et al. 2009). In
this study, we investigated whether ursodeoxycholic acid
(UDCA), a widely used bile acid used therapeutically in
liver diseases, induces GLP-1 secretion, and assessed its
effects on glucose and insulin levels in healthy subjects.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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In this study, we examined 7 subjects (4 men and 3
women). The mean age of the patients was 33.4 ±
7.8 years, and BMI was 20.4 ± 2.4 kg/m2. All the sub-
jects were checked in the periodical health examination
and checked for normal.
Mean changes in plasma glucose, serum IRI, and
plasma active GLP-1 levels, with and without UDCA,
are shown in Figure 1. A significant decrease in plasma
glucose levels, comparing to UDCA intake, was observed
at 30 min (without UDCA, 135 ± 6 mg/dl; with UDCA,
123 ± 3.0 mg/dl, P = 0.012, Figure 1A). Serum IRI levels
tended to increase after UDCA intake, but we found no
statistically significant change at any time point (Figure
1B). However, plasma active GLP-1 levels were increased
by UDCA intake. Significant increases were found at 60,
90, and 180 min (Figure 1C). In addition, we examined
AUCs to determine whether UDCA has a significant im-
pact on metabolic parameters (Figure 2). We found a
significant decrease in AUC of 0–60 min for plasma glu-
cose (without UDCA, 7191 ± 250 mg·min/dl; with
UDCA, 6716 ± 189 mg·min/dl, P = 0.001; Figure 2A),
but no significant change over 0–180 min (without
UDCA, 19,074 ± 273 mg·min/dl; with UDCA, 18,223 ±
842 mg·min/dl, P = 0.050; Figure 2A). With respect to
serum IRI, we found no significant increase in AUCs
over 0–60 and 0–180 min (without UDCA, 1551 ± 418
μU·min/ml; with UDCA, 1941 ± 246 μU·min/ml, P =
0.065; without UDCA, 3117 ± 912 μU·min/ml; with
UDCA, 3590 ± 794 μU·min/ml, P = 0.165, respectively;
Figure 2B). Finally, we found a significant increase in
plasma active GLP-1 levels at AUC of 0–60 min (with-
out UDCA, 450 ± 162 mmol·min/l; with UDCA, 649 ±Figure 1 Results of meal test for (A) plasma glucose, (B) immunoreac
were performed using paired Student’s t-test or Wilcoxon signed rank test.232 mmol·min/l, P = 0.046; Figure 2C); however, over
0–180 min, we found no significant change (without
UDCA, 1230 ± 485 mmol·min/l; with UDCA, 1664 ±
588 mmol·min/l, P = 0.060; Figure 2C).
Discussion
To our knowledge, our study is the first to reveal a sig-
nificant increase in postprandial plasma GLP-1 levels ac-
companied by a significant decrease in postprandial
plasma glucose levels by UDCA intake in healthy sub-
jects. We propose that these effects, increased GLP-1
and decreased glucose, explain, at least in part, the blood
glucose-lowering action of UDCA, through increased
plasma active GLP-1 levels resulting in higher serum in-
sulin levels. Our data and recent findings on TGR5,
which is a bile acid-sensitive GPCR (Maruyama et al.
2002) that enhances GLP-1 secretion (Katsuma et al.
2005; Thomas et al. 2009), suggest that UDCA stimu-
lates GLP-1 secretion via TGR5 signaling. Furthermore,
it was reported that a low carbohydrate/high-fat diet sti-
mulates postprandial GLP-1 levels in healthy subjects
(Numao et al. 2012). Because a high-fat diet elevates the
fecal concentration of bile acids (Cummings et al. 1978;
Bianchini et al. 1989), it is likely that bile acid induced
by high-fat diet stimulates GLP-1 secretion. It follows
that incretin hormones may stimulate insulin secretion
through bile acids induced by fat diet, in addition to the
widely known glucose-dependent pathway (Nauck et al.
1986).
In our study group, we observed a rapid transition of
plasma glucose, serum IRI, and plasma active GLP-1
levels. The AUCs, which showed significant differences
only over 0–60 min for plasma glucose and GLP-1,tive insulin, (C) active GLP-1. Data are means ± SD. Comparisons
* P < 0.05, without UDCA vs. with UDCA.
Figure 2 Results of meal test for AUC of (A) plasma glucose, (B) immunoreactive insulin, (C) active GLP-1. Data are means ± SD.
Comparisons were performed using paired Student’s t-test or Wilcoxon signed rank test. * P < 0.05, without UDCA vs. with UDCA.
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Incretin-based therapies such as GLP-1 receptor ago-
nists and DPP-4 inhibitors are currently in use for the
management of type 2 diabetes. However, these patients
may retain GLP-1 secretion ability, which should be con-
sidered when planning treatment. UDCA is a candidate
factor for evaluating GLP-1 secretion ability, because
consumption of this drug increases plasma active GLP-1
secretion in healthy subjects, as indicated by our results.
We evaluated the effect of UDCA only in healthy sub-
jects; further study in type 2 diabetes patients is neces-
sary to test this idea. Furthermore, UDCA is usually
administered to patients with liver cirrhosis or chronic
hepatitis, frequently suffering from abnormal glucose
metabolism. It is possible that UDCA improves glucose
intolerance in those patients. For example, nonalcoholic
steatohepatitis patients treated with high-dose UDCA
experienced significant reductions in serum glucose, gly-
cosylated hemoglobin, and serum insulin levels (Ratziu
et al. 2011).
Interestingly, there was no statistically significant dif-
ference in insulin secretion (Figures 1B and 2B) induced
by UDCA. A previous study showed that a high-fat diet,
which induces bile acids secretion, stimulates GLP-1 se-
cretion and lowers insulin levels transiently in the early
phase (Numao et al. 2012). Thus, the effect of UDCA on
insulin secretion should be evaluated on a finer time
scale.
One limitation of our study is the small sample size.
We studied only 7 subjects and the results varied widely.
For example, statistically significant differences in
plasma active GLP-1 levels were found unexpectedly at0 min (without UDCA, 4.6 ± 2.8 pmol/l; with UDCA,
7.1 ± 3.9 pmol/l, P = 0.032, Figure 1C). Further study
with a larger number of subjects is warranted.
Conclusions
In conclusion, UDCA increased GLP-1 secretion in
healthy subjects. We propose that this drug may be use-




Seven people were recruited for this study. All subjects
were non-obese (body mass index (BMI) < 25). Written
informed consent was obtained from all participants
with the approval of the ethics committee of Toshima
Hospital.
Meal tolerance tests
Meal tolerance tests were performed after an overnight
fast. The test meal was authorized by the Japan Diabetes
Society; total caloric content of the meal was 460 kcal
(carbohydrates, 56.5 g; protein, 18 g; fat, 18 g; JANEF
E460F18, Q.P. Corporation, Tokyo, Japan). The test meal
was ingested within 15 min. Blood samples were col-
lected at 0, 30, 60, 90, 120, and 180 min after the meal.
One week later, testing was performed again, with intake
of UDCA 200 mg (5% granule, Urso, Mitsubishi Tokyo
Pharmaceuticals) after the test meal.
Levels of glucose, immunoreactive insulin (IRI), and
active GLP-1 in sera or plasma were measured at each
time point. Plasma glucose concentrations were mea-
sured by the glucose oxidase method. IRI levels were
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GLP-1 samples were analyzed using ELISA (EGLP-35 K;
Linco Research Inc., MO, USA). Plasma active GLP-1
concentrations were measured in plasma after addition
of DPP-4 inhibitor (10 μl/ml blood; Linco Research Inc.,
MO, USA).
Statistical analysis
Data are presented as means ± standard deviation (SD).
Statistical calculations including areas under the curve
(AUCs) were carried out using paired Student’s t-test or
Wilcoxon signed rank test, as appropriate. A P value <
0.05 was taken to indicate a significant difference.
Normality of the data was evaluated by the Shapiro-
Wilk test.
Competing interests
The authors declare they have no competing interests in relation to this
article.
Authors’ contributions
All authors participated in the preparation of the manuscript, and read and
approved the final manuscript.
Acknowledgments
We thank Drs Tatsuaki Goto, Ryuki Kawamura, Junnosuke Hayasaka, and
Hiromi Matsuura (junior residents, Tokyo Metropolitan Health Medical
Treatment Corporation Toshima Hospital) for data collection.
Author details
1Division on Endocrinology and Metabolism, Tokyo Metropolitan Health
Medical Treatment Corporation Toshima Hospital, Itabashi, Japan. 2Tokyo
Metropolitan Geriatric Hospital, Itabashi, Japan.
Received: 16 October 2012 Accepted: 13 January 2013
Published: 22 January 2013
References
Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2
diabetes: systematic review and meta-analysis. JAMA 298:194–206
Bianchini F, Caderni G, Dolara P, Fantetti L, Kriebel D (1989) Effect of dietary fat,
starch and cellulose on fecal bile acids in mice. J Nutr 119:1617–1624
Campbell RK, Miller S (2009) New therapeutic horizons: mapping the future of
glycemic control with incretin-based therapy. Diabetes Educ 35:731–734,
738–740, 742–734 passim
Chen L, McNulty J, Anderson D, Liu Y, Nystrom C, Bullard S, Collins J, Handlon AL,
Klein R, Grimes A, Murray D, Brown R, Krull D, Benson B, Kleymenova E,
Remlinger K, Young A, Yao X (2010) Cholestyramine reverses hyperglycemia
and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker
diabetic fatty rats. J Pharmacol Exp Ther 334:164–170
Cummings JH, Wiggins HS, Jenkins DJ, Houston H, Jivraj T, Drasar BS, Hill MJ
(1978) Influence of diets high and low in animal fat on bowel habit,
gastrointestinal transit time, fecal microflora, bile acid, and fat excretion.
J Clin Invest 61:953–963
Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes
satiety and suppresses energy intake in humans. J Clin Invest 101:515–520
Garg SK, Ritchie PJ, Moser EG, Snell-Bergeon JK, Freson BJ, Hazenfield RM (2011)
Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type
1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab
13:137–143
Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C (1999)
Glucagon-like peptide-1 promotes satiety and reduces food intake in
patients with diabetes mellitus type 2. Am J Physiol 276:R1541–1544
Katsuma S, Hirasawa A, Tsujimoto G (2005) Bile acids promote glucagon-like
peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-
1. Biochem Biophys Res Commun 329:386–390Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7–
36: a physiological incretin in man. Lancet 2:1300–1304
Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura
T, Itadani H, Tanaka K (2002) Identification of membrane-type receptor for
bile acids (M-BAR). Biochem Biophys Res Commun 298:714–719
Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H, Itoh H (2009) Serum bile
acid along with plasma incretins and serum high-molecular weight
adiponectin levels are increased after bariatric surgery. Metabolism
58:1400–1407
Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W
(1986) Incretin effects of increasing glucose loads in man calculated from
venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492–498
Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, Creutzfeldt W
(1989) Insulinotropic properties of synthetic human gastric inhibitory
polypeptide in man: interactions with glucose, phenylalanine, and
cholecystokinin-8. J Clin Endocrinol Metab 69:654–662
Numao S, Kawano H, Endo N, Yamada Y, Konishi M, Takahashi M, Sakamoto S
(2012) Short-term low carbohydrate/high-fat diet intake increases
postprandial plasma glucose and glucagon-like peptide-1 levels during an
oral glucose tolerance test in healthy men. Eur J Clin Nutr 66:926–931
Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK,
Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB (2009) Serum
bile acids are higher in humans with prior gastric bypass: potential
contribution to improved glucose and lipid metabolism. Obesity (Silver
Spring) 17:1671–1677
Plaisancie P, Dumoulin V, Chayvialle JA, Cuber JC (1995) Luminal glucagon-like
peptide-1(7–36) amide-releasing factors in the isolated vascularly perfused
rat colon. J Endocrinol 145:521–526
Prigeon RL, Quddusi S, Paty B, D’Alessio DA (2003) Suppression of glucose
production by GLP-1 independent of islet hormones: a novel extrapancreatic
effect. Am J Physiol Endocrinol Metab 285:E701–E707
Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C,
Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP,
Riviere M, Spenard J, FRESGUN (2011) A randomized controlled trial of high-
dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol
54:1011–1019
Shang Q, Saumoy M, Holst JJ, Salen G, Xu G (2010) Colesevelam improves insulin
resistance in a diet-induced obesity (F-DIO) rat model by increasing the
release of GLP-1. Am J Physiol Gastrointest Liver Physiol 298:G419–G424
Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, Futami-Suda S, Yasuoka H,
Ouchi M, Suzuki K, Kigawa Y, Nakano H (2007) Colestimide lowers plasma
glucose levels and increases plasma glucagon-like PEPTIDE-1 (7–36) levels in
patients with type 2 diabetes mellitus complicated by hypercholesterolemia.
J Nihon Med Sch 74:338–343
Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A,
Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K
(2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell
Metab 10:167–177
Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D (2001) Glucose-
dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells
by pleiotropic signaling. Mol Endocrinol 15:1559–1570
Xu G, Kaneto H, Lopez-Avalos MD, Weir GC, Bonner-Weir S (2006) GLP-1/exendin-
4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. Diabetes
Res Clin Pract 73:107–110
doi:10.1186/2193-1801-2-20
Cite this article as: Murakami et al.: Incretin secretion stimulated by
ursodeoxycholic acid in healthy subjects. SpringerPlus 2013 2:20.
